Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Berenberg Bank analyst Kerry Holford maintained a Hold rating on Novartis (NVS – Research Report) yesterday and set a price target of $97.00.

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years.

Below is Validea's guru fundamental report for NOVARTIS AG (ADR) (NVS). Of the 22 guru strategies we follow, NVS rates highest using our Multi-Factor Investor model based on the published strategy ...

NEW YORK, March 13 (Reuters) - The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis (NOVN.S), opens new tab ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

ZURICH, Feb 25 (Reuters) - Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero Prostate Cancer’s Blitz the Barriers, a project designed to address ...